ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Overexpression of Pleckstrin Homology Domain-Containing Family A Member 4 Is Correlated with Poor Prognostic Outcomes and Immune Infiltration in Lower-Grade Glioma

Huang, Baojun; Pan, Weijun; Wang, Wenchao; Wang, Yijian; Liu, Pan; Geng, Wujun*南方医科大学; 1
DISEASE MARKERS2022-11-11DOI: 10.1155/2022/1292648
2被引9阅读
引用收藏
分享

摘要

Introduction. The global incidence of brain tumors, the most common of which is lower grade glioma (LGG), remains high. Pleckstrin homology domain-containing family A member 4 (PLEKHA4) has been reported to be related to tumor invasion and growth. However, its role and correlation with immunity in LGG remain elusive. Methods. We evaluated the expression pattern, prognostic value, biological functions, and immune effects of PLEKHA4 in LGG. We also analyzed the association between PLEKHA4 levels in different tumors, patient prognosis, and its role in tumor immunity. Depending on the type of research data, we used statistical methods such as Student's t-tests, Mann-Whitney U tests one-way ANOVA tests Kruskal-Wallis tests Pearson's or Spearman's correlation analysis Chi-square and Fisher's exact tests in this paper. Results and Conclusions. The results revealed that PLEKHA4 levels were markedly elevated in most tumors (such as LGG). High PLEKHA4 levels are associated with poor overall survival (OS), progression-free interval (PFI) rates, and disease-specific survival (DSS) in LGG patients. Cox regression analysis and nomograms showed that PLEKHA4 levels are independent prognostic factors for LGG patients. According to functional enrichment analysis, PLEKHA4 levels in LGG are associated with immune infiltration and immunotherapy. In conclusion, PLEKHA4 is a potential prognostic marker and immunotherapy target for LGG.

学科与关键词

关键词
CENTRAL-NERVOUS-SYSTEMTUMORSBRAINIDH
相关
加载中…
  • PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma
    Zhi, Wenqian; Wang, Ye; Jiang, Chenyu; Gong, Yuqin; Chen, Qiuyan; Mao, Xiang*; Deng, Wensheng*; Zhao, Shasha*Frontiers in Immunology, 2023, 14: 1128244.被引 1
  • Identification of COL1A1 associated with immune infiltration in brain lower grade glioma
    Ren, Junyu; Da, Junlong; Hu, Narisu*PLoS One, 2022, 17(7).被引 3
  • PTPRN Serves as a Prognostic Biomarker and Correlated with Immune Infiltrates in Low Grade Glioma
    Li, Peng; Chen, Fanfan; Yao, Chen; Zhu, Kezhou; Zhang, Bei; Zheng, Zelong*Brain Sciences, 2022, 12(6): 763.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
DISEASE MARKERS
发表日期
2022-11-11
卷期
第 2022 卷
页码
1292648
DOI
10.1155/2022/1292648
语言
ENGLISH
期刊等级
4区
成果收录
SCIE
资助标注
National Natural Science Foundation of China; Wenzhou Science and Technology Project; Zhejiang Public Welfare Technology Research Plan; [81774109]; [81973620]; [ZY2019015]; [LGD20H290002]

作者

  • H

    Huang, Baojun (第一作者)

    1 · wenzhou med univ

  • P

    Pan, Weijun

    southern med univ

查看全部 6 位作者收起作者
  • W

    Wang, Wenchao

    1 · wenzhou med univ

  • W

    Wang, Yijian

    1 · wenzhou med univ

  • L

    Liu, Pan

    1 · wenzhou med univ

  • G

    Geng, Wujun (通讯)

    1 · wenzhou med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417